Navigation Links
OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Date:4/30/2009

BOTHELL, WA and VANCOUVER, April 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company's first quarter financial results will be released on Thursday May 7, 2009, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's first quarter results and provide an update on the business and product pipeline.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 800-967-7143 (U.S. & Canada) or 719-325-2413 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that the ... and Mexico currently faces ... approved agents, the anticipated label extension of Boehringer ... of emerging biologics will substantially increase the competitiveness ... IL-5 inhibitors will introduce a new dynamic to the ...
(Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... , ... ... ... ...
... ... ... ... ...
... , ... ... ... , ...
Cached Biology Technology:YM sees nimotuzumab license unaffected by civil claim against licensor 2YM sees nimotuzumab license unaffected by civil claim against licensor 3YM sees nimotuzumab license unaffected by civil claim against licensor 4YM sees nimotuzumab license unaffected by civil claim against licensor 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 2Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 3Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 4Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 2InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 3InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 4InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 5InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 7
(Date:8/21/2014)... improving the food intake, health and quality of life ... three projects at the University of Waterloo receiving close ... of Health Research (CIHR). , Professor Heather Keller, ... and a Schlegel research chair in nutrition and aging, ... many Canadians living in long-term care homes are poorly ...
(Date:8/21/2014)... finding that has implications for life in other extreme ... solar system, LSU Associate Professor of Biological Sciences Brent ... Foundation, or NSF, this week published a paper confirming ... lies 800 meters (2600 feet) beneath the surface of ... Given that more than 400 subglacial lakes and numerous ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Water window imaging opportunity 2
... New species are not just discovered in exotic localeseven ... new plants and animals. Academy scientists recently named a ... of fishes distantly related to sharks, from the coast ... species, the Eastern Pacific black ghostshark ( Hydrolagus melanophasma ...
... , , SEATTLE, Sept. ... leading provider of specialized reference laboratory and contract research services, today ... Terry M. Giles, providing for a $4 million loan (the "Loan") ... the Loan, on August 31, 2009, the Company also repurchased 2,391,906 ...
... , NEW YORK, Sept. 8 ... in its catalogue. , , ... http://www.reportlinker.com/p0131250/Carbon-Dioxide-Monitors.html , , This report ... of US$ by the following segments: End-tidal Carbon Dioxide (EtCO2) ...
Cached Biology News:New species of ghostshark from California and Baja California 2Pacific Biometrics Completes $4 Million Debt Financing 2Pacific Biometrics Completes $4 Million Debt Financing 3Pacific Biometrics Completes $4 Million Debt Financing 4Pacific Biometrics Completes $4 Million Debt Financing 5Reportlinker Adds Carbon Dioxide Monitors Report 2Reportlinker Adds Carbon Dioxide Monitors Report 3Reportlinker Adds Carbon Dioxide Monitors Report 4Reportlinker Adds Carbon Dioxide Monitors Report 5Reportlinker Adds Carbon Dioxide Monitors Report 6Reportlinker Adds Carbon Dioxide Monitors Report 7Reportlinker Adds Carbon Dioxide Monitors Report 8Reportlinker Adds Carbon Dioxide Monitors Report 9
... set the standard for sample concentration and drying. ... chamber uses a combination of centrifugal force, heat ... single run. , SC210A comes equipped with:, ... lasting chemical compatibility ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
... Jouan RC Standard MB (For small quantities ... biology samples) of vacuum concentrator/centrifugal evaporator systems ... and biochemistry for rapid and safe concentration ... be expanded with pumps, different of cold ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: